

EXPORT LICENSE

NRC FORM 250



United States of America
Nuclear Regulatory Commission
Washington, D.C. 20555

NRC LICENSE NO.: XMAT448/02

Page 1 of 11

NRC DOCKET NO.: 11006349

LICENSE EXPIRES: December 31, 2025

Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations hereof made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

LICENSEE

Cambridge Isotope Laboratories, Inc.
50 Frontage Road
Andover, MA 01810

Attn: Rebecca Dabkowski

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)

See following page(s)

INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)

See following page(s)

OTHER U.S. PARTY(IES) TO EXPORT

See following page(s)

APPLICANT'S REFERENCE: XMAT448

ULTIMATE DESTINATION: India

QUANTITY(IES)

DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)

This license is amended to update the list of ultimate foreign consignees by adding 3 additional parties.

The license is authorized to export a cumulative total of 10,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds. The cumulative total starts from the issuance of the original export license XMAT448.

Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.

This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC.

THIS LICENSE IS INVALID UNLESS SIGNED BELOW BY AUTHORIZED NRC REPRESENTATIVE

SIGNATURE:

Peter J. Habighorst
Digitally signed by Peter J. Habighorst
Date: 2020.12.31 07:17:32 -05'00'

NAME AND TITLE:









Peter J. Habighorst, Acting Deputy Director
Office of International Programs

DATE OF ISSUANCE:

December 31, 2020

EXPORT LICENSE

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1. 
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
2. 
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
3. 
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
4. 
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
5. 
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
6. 
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
7. 
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
8. 
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

9. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
10. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
11. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
12. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
13. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
14. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
15. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
16. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

17. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
18. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
19. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
20. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
21. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
22. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
23. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
24. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

25. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
26. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
27. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
28. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
29. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
30. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
31. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
32. [REDACTED]
India
(non-nuclear end use in active pharmaceutical ingredient (API) production)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

33.

[REDACTED]

India

(non-nuclear end use in active pharmaceutical ingredient (API) production)

34.

[REDACTED]

India

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

35.

[REDACTED]

India

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

36.

[REDACTED]

India

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

37.

[REDACTED]

India

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

38.

[REDACTED]

India

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

39.

[REDACTED]

India

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

40.

[REDACTED]

India

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

41. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
42. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
43. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
44. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
45. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
46. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
47. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
48. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

49. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
50. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
51. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
52. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
53. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
54. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
55. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
56. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

57. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
58. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
59. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
60. [REDACTED]
India
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1. [REDACTED]
India
(for distribution to ultimate consignees)
2. [REDACTED]
India
(for distribution to ultimate consignees)
3. [REDACTED]
India
(for distribution to ultimate consignees)

INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

4. [REDACTED]

India

(for distribution to ultimate consignees)

5. [REDACTED]

France

(for distribution to ultimate consignees)

6. [REDACTED]

India

(for distribution to ultimate consignees)

7. [REDACTED]

India

(for distribution to ultimate consignees)

8. [REDACTED]

India

(for distribution to ultimate consignees)

9. [REDACTED]

India

(for distribution to ultimate consignees)

10. [REDACTED]

India

(for distribution to ultimate consignees)

OTHER U.S. PARTY(IES) TO EXPORT:

1. Cambridge Isotope Laboratories, Inc.
50 Frontage Road
Andover, MA 01810
(supplier/distributors)
2. Cambridge Isotope Laboratories, Inc.
6 Highwood Drive
Tewksbury, MA 01876
(supplier)
3. Cambridge Isotope Separations
1689 Burnett Drive
Xenia, OH 45385
(supplier)